Bemfivastatin
Product Specifications
UNSPSC Description
Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320 mg/kg/day for rats developmental toxicity, 12.5 mg/kg/day for rabbits maternal toxicity, and 25 mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins[1][2].
Target Antigen
HMG-CoA Reductase (HMGCR)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/bemfivastatin.html
Purity
99.48
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(C[C@H](O)C[C@H](O)CCN1C(C2=CC=C(F)C=C2)=C(C3=CC=CC=C3)C(C(NC4=CC=C(CO)C=C4)=O)=C1C(C)C)=O
Molecular Weight
588.67
References & Citations
[1]Faqi AS, et al. Developmental toxicity of the HMG-CoA reductase inhibitor (PPD10558) in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):23-37.|[2]Wierzbicki A, et al. Drugs in development for the management of dyslipidaemia[J]. Future Prescriber, 2012, 13(2): 12-15.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-106281/Bemfivastatin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-106281/Bemfivastatin-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
805241-79-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
